TrianglePembrolizumab (NCT06377540)
Pembrolizumab trial for Autologous Stem Cell Transplant (NCT06377540). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory classical Hodgkin lymphoma who qualify for an autologous stem-cell transplant using BEAM chemotherapy.
The idea: add pembrolizumab before transplant and restart it about a month afterward, every three weeks for one year. Pembrolizumab blocks PD-1, an immune brake. BEAM combines carmustine, etoposide, cytarabine and melphalan before patients receive their own stem cells. Researchers measure survival without progression and monitor safety; this is one treatment group.
This phase 2 study plans 28 patients. The University of Minnesota's Masonic Cancer Center recruits in Minneapolis.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.